Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO
The blockbuster public offering pegs Allogene's market value at more than $2 billion. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursd.....»»
How a small biotech worked its way out of storage space during the industry"s biggest conference
The eight-person company scored a $10 million Series A round last year with its new approach for defeating cancer......»»
Bay Area cancer-fighting biotech hikes IPO target by 25 percent
ORIC Pharmaceuticals Inc. on Thursday increased the amount it hopes to raise in its upcoming IPO by 25 percent. The South San Francisco cancer-focused biotech now hopes to raise up to $115 million in an offering that could value the company at more.....»»
Cancer-fighting Peninsula biotech targets $100M IPO
The Redwood City company raised $226 million in three venture rounds after its formation five years ago by Third Rock Ventures......»»
Buffalo-based biotech startup inks deal with Chinese pharma giant worth up to $148 million
MimiVax has long presented an exciting opportunity to develop a cutting-edge cancer therapy in Buffalo. Now the spinout from Roswell Park Comprehensive Cancer Center is a lot closer to that goal. The company – which is developing an anti-cancer .....»»
Mountain View biotech boosts targets by 40% ahead of Wednesday IPO
Cancer-fighting IGM Biosciences Inc. increased by about 40 percent the number of shares it plans to sell in an IPO that is scheduled to price Tuesday afternoon. The Mountain View-based biotech now plans to sell about 10.9 million shares to the publi.....»»
Mountain View biotech sets targets to raise up to $153M in IPO
IGM Biosciences Inc., a pre-revenue biotech company developing antibody therapies for cancer, set price targets on Tuesday for an IPO in which it hopes to raise up to $153 million. The Mountain View company is one of three Bay Area businesses that s.....»»
Cancer-fighting biotech hopes to raise $100M in IPO
IGM Biosciences Inc., a pre-revenue biotech developing antibody therapies for cancer, filed on Monday to raise up to $100 million in an IPO. The Mountain View company is one of two Bay Area biotechs that filed plans to go public this week. Pleasant.....»»
How this Peninsula biotech plans to turn a $100 million round into "next generation" of cancer drugs
After its acquisition of Warp Drive Bio last year, this Redwood City biotech company took its cancer-fighting trek into the "undruggable" universe......»»
Genentech, Roche vets aim new company"s $86.25 million IPO at cancer
A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering. RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to us.....»»
Merck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 million
Merck & Co. Inc. said Monday it was buying privately held biopharmaceutical company Tilos Therapeutics, in a deal that could be valued at up to $773 million. The deal includes an upfront payment and contingent milest.....»»
Adaptive Biotechnologies files for $230M initial public offering
The Seattle-based biotech company spun out of the Fred Hutchinson Cancer Research Center in 2009 and has independently raised more than $400 million in funding......»»
3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million
From rare diseases to cancer and NASH, this trio of companies would be the seventh, eighth and nine Bay Area life sciences IPOs this year......»»
Athenex just raised $100 million. Here"s what it means
The wheels of progress turn slowly in the biomedical world. But the news this morning that Athenex has scored $100 million in new investment is another sign that big things are coming for the Buffalo-based developer of cancer therapies. Among the .....»»
Chinese investors lead another monster round for Menlo Park early cancer detection unicorn
Looking to detect cancer early through a simple blood test, Grail Inc. scored $300 million in new funding from several Chinese investors on top of the $1.2 billion it raised over the past two years. The Menlo Park company, which was rumored to be .....»»
This Biotech Just Had a $903 Million IPO—And It’s Disappointed
Cancer drug maker BeiGene was looking to score $1 billion in its secondary listing in Hon.....»»
Cancer-fighting startup lands nearly $19 million as Texas hands out more grants to combat disease
Forbius, a company developing drugs to fight cancer, has scored $18.5 million from the state of Texas to advance its pharmaceuticals. The business operates legally as Formation Biologics Corp. and was founded in Montreal, Canada, in 2011 as a spinoff.....»»
Two more Peninsula IPOs tell the story of biotech"s investment boom
And then there were 15. Two Bay Area biotech companies — one that started its first clinical trial in eye diseases in July, the other a pioneer in the fledgling field of hunting down cancer via a simple blood draw — seek to raise $100 million eac.....»»
RiverVest leads $40 million venture capital deal
Clayton-based venture capital firm RiverVest Venture Partners has led a $40 million Series B financing round for a Seattle-based biotech company. The company, OncoResponse, is developing a portfolio of antibodies to high-value targets for cancer t.....»»
This cancer-fighting biotech sped from startup to IPO filing in 10 months
The team that took Kite Pharma from a startup re-engineering a patient's own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie B.....»»
Pediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPO
Pediatric cancer biot.....»»